About this episode
The FDA's rejection of MDMA as a treatment may well be a short-term setback for legally helping people with PTSD and other disorders. Mason Marks of Harvard Law School’s Petrie-Flom Center for Health Law Policy offers his assessment. Hosted on Acast. See acast.com/privacy for more information.